The Liver Meeting 2019-Precision Treatment of HBV: Envisioning Curative Therapies*

Precision Treatment of HBV: Envisioning Curative Therapies*

Video Transcription

Video Summary

The video transcript discusses the case of a 29-year-old accountant with chronic hepatitis B infection treated with oral nucleosides for 3.5 years who now wants to stop treatment. It explores the expected outcomes if the drug is discontinued, the clinical value of using quantitative hepatitis B surface antigen in monitoring therapeutic response, and the emerging therapies for chronic hepatitis B. The focus is shifting towards achieving surface antigen loss off-treatment for a finite course of treatment, as studies show this reduces the risk of liver cancer. New therapies targeting various stages of the virus life cycle and immune modulation are being researched. Biomarkers like hepatitis B surface antigen quantitation and genotype may help in decision-making for treatment withdrawal. The goal is to move towards functional and ultimately sterilizing cure, eliminating CCC DNA from the liver.

Asset Caption

Presenter: Norah Terrault

Keywords

chronic hepatitis B

nucleoside treatment

hepatitis B surface antigen

therapeutic response monitoring

emerging therapies

CCC DNA elimination